Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 12 for:    rolapitant

Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02991456
Recruitment Status : Recruiting
First Posted : December 13, 2016
Last Update Posted : July 30, 2020
Sponsor:
Collaborator:
TerSera Therapeutics
Information provided by (Responsible Party):
Duke University

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 15, 2021
Estimated Study Completion Date : April 27, 2021